There is known substantial variation in non-surgical opioid prescribing but there is limited data characterizing opioid use in the postoperative period, though recommendations exist to limit postoperative narcotic prescriptions to 7 days, or 200mg oral morphine equivalents (OME). We sought to evaluate variation of postoperative opioid prescribing after inpatient urologic surgery in a national VA population, hypothesizing that we would identify considerable variation in opioid prescribing behavior following common major urologic surgery.
INTRODUCTION AND OBJECTIVES:
There is known substantial variation in non-surgical opioid prescribing but there is limited data characterizing opioid use in the postoperative period, though recommendations exist to limit postoperative narcotic prescriptions to 7 days, or 200mg oral morphine equivalents (OME). We sought to evaluate variation of postoperative opioid prescribing after inpatient urologic surgery in a national VA population, hypothesizing that we would identify considerable variation in opioid prescribing behavior following common major urologic surgery.
METHODS: Using the VA Corporate Data Warehouse (CDW), we retrospectively identified all patients who underwent open or minimally invasive (MIS) nephrectomy, prostatectomy, cystectomy, transurethral resection or photovaporization of the prostate from 1/1/2014 -12/31/2016 at a VA Medical Center. We obtained demographic, operative, and discharge opioid prescription (Rx) data for each case. We used chisquared tests, quantile regression and a multivariable logistic regression model to characterize the relationship between a priori identified covariates with prescribed OME.
RESULTS: We identified 19,823 patients who underwent one of the candidate procedures from 2014-2016. The average age was 67 years and procedures were evenly divided by geographic region and year. Across all procedures there was a very large range of prescribed postoperative opioid dose, from 0 to 7560mg OME, with a median of 225mg OME excluding TURP/PVP (Figure 1 ). We did not observe any difference in prescribed postoperative OME between open and MIS procedures. Those in the highest quartile of OME dose were more likely to be younger, have slightly increased LOS, have undergone surgery in a teaching facility or in the South, or have filled an opioid Rx within 90 days before surgery. However, pre-operative opioid use only explained 5% of observed variance.
CONCLUSIONS: These data reveal very high post-operative opioid Rx doses and substantial variation after common inpatient urologic surgeries. The vast majority exceed current opioid prescribing recommendations and remain high even for populations expected to have significantly lower pain requirements including MIS and opioid-naive patients. These data identify a significant opportunity for improvement in postoperative opioid prescribing.
Source of Funding: none

MP44-02 POST-OPERATIVE NARCOTIC PRESCRIBING PATTERNS FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY
Elizabeth Green*, Petria Thompson, Kristen Scarpato, Kirk Keegan, Sam Chang, David Penson, Daniel Barocas, Matthew Resnick, Nashville, TN INTRODUCTION AND OBJECTIVES: Narcotic use is a growing public health concern and recent guidelines have been proposed to guide post-operative prescribing behavior. The aim of this study was to characterize post-operative narcotic prescribing patterns for patients undergoing radical cystectomy at a single quaternary care referral center.
METHODS: We performed a retrospective cohort study comprising all patients residing in Tennessee or contiguous states who underwent radical cystectomy at a single institution from January 2013 to August 2015. Controlled substances data were obtained from the Tennessee Controlled Substances Medication Database from 1 year prior to surgery through 1 year after surgery and linked to clinical and demographic data abstracted from the medical record.
RESULTS: 267 patients underwent radical cystectomy with 134 (50%) patients filling a prescription for a narcotic in the year prior to surgery and 183 (69%) patients filling a narcotic prescription in the year following surgery. The mean total filled morphine equivalent dose (MED) in the 30 days following surgery was 585.46 AE 761.5 mg (table  1) , median 450mg (IQR 300-600mg). Therefore, the median narcotic dose was more than twice the proposed 200mg MED limit on discharge prescriptions for acute post-operative pain. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e627 41 patients filled a second prescription for a narcotic within 30 days, a refill rate of 15.4%. Compared to the patients who did not require a refill, these patients were more likely to have been taking narcotics in the pre-operative period(43.3% vs 87.8%, P<0.001). Of the 41 patients who required a narcotic refill, 36 patients were on preoperative narcotics and of the remaining 5 who were not, 3 had a high grade complication and one patient had metastatic disease at the time of surgery. Therefore, of the 267 patients who underwent radical cystectomy, only 1 opioid naive, non-metastatic patient without a high grade complication required an additional prescription for a narcotic within one month of surgery.
CONCLUSIONS: Overprescription of opioid analgesics is common in the postoperative period. Multi-faceted improvement programs must be implemented to address the downstream public health implications of opioid overprescription around the time of surgery.
Source of Funding: None
MP44-03 KEY OPINION LEADERS MOTIVATE INCREASED PRESCRIPTIONS AMONG THEIR LOCAL PHYSICIANS
Austin Lee, Omar Ayyash*, Avinash Maganty, Liam Macleod, Jathin Bandari, Benjamin Davies, Bruce Jacobs, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Key opinion leaders have become intimately entwined with the marketing of pharmaceuticals and medical devices. There is currently no consensus on what constitutes a key opinion leader and no quantitative mechanism for identifying them. We explored the utility of a new metric for identifying key opinion leaders and their influence on local prescription patterns.
METHODS: Using abiraterone and enzalutamide as a model, we defined key opinion leaders as those physicians receiving the top payment in a health referral region (HRR). HRRs were delineated according to the Dartmouth Health Atlas. Physicians, including key opinion leaders, were grouped into the HRRs by zip code. Payment data was abstracted from the 2016 Open Payments Database and linked to the Medicare Part D database for prescription count and drug cost.
RESULTS: Across the 306 health referral regions, the median top payment was $188 and $176 for enzalutamide and abiraterone, respectively. The median number of prescriptions was 126 for enzalutamide and 147 for abiraterone. There was a significant correlation between increasing top payment to an individual and increasing total prescriptions in the same region (enzalutamide rho [ 0.69, p < 0.001; abiraterone rho [ 0.65, p < 0.001) CONCLUSIONS: The Open Payments database may be used to establish a quantitative metric for identifying key opinion leaders and early analysis indicates that higher paid individuals motivate more prescriptions from other physicians in their region. 
MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Craig Labbate*, Brittany Adamic, Chicago, IL; Pooja Talaty, Avisek Datta, Chi-Hsiung Wang, Brian T Helfand, Evanston, IL INTRODUCTION AND OBJECTIVES: In June of 2011, the US Food and Drug Administration (FDA) released a safety announcement stating healthcare professionals should be aware of the increased risk of high-grade prostate cancer after starting 5-alpha reductase inhibitors (5ARI) including finasteride and dutasteride. This was in response to data from the REDUCE and PCPT trials which demonstrated a small increase in the frequency of Gleason score 8-10 tumor biopsies after 5ARI use. We aimed to evaluate the influence of these trials and the FDA safety warning on the 5ARI prescription practices across a large healthcare system. METHODS: The electronic medical records were used to identify new prescriptions for any 5ARI in the 5 years before and after the 2011 FDA safety announcement. We determined rates of prescription to adjust for changing patient volume over time. In a secondary analysis, the prescription rates of 5ARI over time among men diagnosed with BPH or Prostate cancer during this time interval were compared. The prescription rates were also compared based upon prescribing physician specialty. RESULTS: Over the 11 year study period, 16,610 unique patients were initiated on 5ARI therapy. Accounting for changing healthcare volume over time, there was a relative rate reduction of 41% (1.96% v 1.16%, p<0.001) for all new prescriptions of a 5ARi after the 2011 FDA safety warning. In men receiving prescriptions who carried a diagnosis of BPH (n[7714), there was a 49% relative decrease in the prescription rate (33.7% vs 17.3%. (p<0.001). In patients with prostate cancer who received a 5ARI (n[975), a 15% relative reduction in new prescriptions was seen in the same time period (10.4% v 8.8% p[0.006). Finally, there was no change in prescription patterns within the urology practice in the 5 years before and after the FDA warning, whereas primary care providers showed a 60% relative reduction in prescription rates (p<0.001).
CONCLUSIONS: Within a large healthsystem, the rate of prescriptions for 5 ARIs has decreased after the FDA safety warning in 2011. This decrease was most pronounced among men with a known diagnosis of BPH who may otherwise benefit from 5ARI treatment of urinary symptoms. Further research is warranted to determine whether these findings reflect national trends.
